SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours
1993
SR 4233: A New Anticancer Drug Targeting Hypoxic Tumors
publication
Evidence: moderate
Author Information
Author(s): J.M. Brown
Primary Institution: Stanford University
Hypothesis
Can SR 4233 effectively kill hypoxic tumor cells while sparing normal tissues?
Conclusion
SR 4233 shows significant potential in preferentially killing hypoxic tumor cells, enhancing the effectiveness of radiation therapy.
Supporting Evidence
- SR 4233 preferentially kills hypoxic cells, which are often resistant to standard therapies.
- Preclinical studies indicate that SR 4233 can significantly enhance the effectiveness of radiation therapy.
- SR 4233 is currently undergoing Phase I clinical testing.
Takeaway
SR 4233 is a special medicine that can kill cancer cells that don't get enough oxygen, helping doctors treat tumors better.
Methodology
The review discusses the cytotoxicity of SR 4233 in various cell lines and its mechanism of action under hypoxic conditions.
Limitations
The study primarily focuses on preclinical data, and clinical efficacy in humans remains to be established.
Want to read the original?
Access the complete publication on the publisher's website